Skip to main content
An official website of the United States government

mosunetuzumab-axgb

View Patient Information
A bispecific, humanized monoclonal antibody with potential antineoplastic activity. Mosunetuzumab contains two antigen-recognition sites: one for human CD3, a T-cell surface antigen, and one for human CD20, a tumor-associated antigen (TAA) that is exclusively expressed on B cells during most stages of B-cell development and is often overexpressed in B-cell malignancies. Upon administration, mosunetuzumab binds to both T cells and CD20-expressing tumor B cells; this cross-links T cells to tumor cells, and may result in a potent cytotoxic T-lymphocyte (CTL) response against CD20-expressing tumor B cells.
Synonym:anti-CD20 x anti-CD3 bispecific monoclonal antibody BTCT4465A
CD20/CD3 BiMAb BTCT4465A
mosunetuzumab
US brand name:Lunsumio
Code name:BTCT 4465A
BTCT-4465A
BTCT4465A
RG 7828
RG-7828
RG7828
RO7030816
Search NCI's Drug Dictionary